Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2019 | FIERCE-22 trial: vofatamab with pembrolizumab for urothelial carcinoma

Here, Arlene Siefker-Radtke, MD, of the University of Texas MD Anderson Cancer Center, Houston, TX, provides an updates of the FIERCE-22 trial (NCT03123055) looking vofatamab with pembrolizumab for urothelial carcinoma. This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.